FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer
TLDR
In patients studied, the FOLFOX-4 combination was shown to be an effective and well-tolerated therapeutic option for treating inoperable metastatic colorectal cancer.Abstract:
In Cuba, colorectal cancer (CRC) is the malignant neoplasm with the fourth-highest incidence and third-highest mortality. Over one-third of CRC patients exhibit metastatic disease at the time of diagnosis. Standard treatment for metastatic CRC is a 5-fluorouracil (5-FU) + Folinic Acid (FA) continuous infusion regimen. International studies have shown, however, that systemic therapy using oxaliplatin combined with 5-FU and FA (FOLFOX-4) improves results in terms of both tumor response and survival in patients with inoperable metastatic CRC. Objective Evaluate the FOLFOX-4 regimen as a first-line therapy for patients with inoperable metastatic CRC in Cuba. Methods FOLFOX-4 therapy was administered to 56 patients with metastatic CRC, in a treatment cycle repeated every 2 weeks for 6-8 cycles. Patients were followed up for a period of 2 years. Results Objective response was attained in 44.6% of patients, and complete response in 12.5%. Median duration of response and of progression-free survival was 9.6 and 8.9 months, respec- tively. Estimated survival at 2 years was 17% (95% CI: 6.89- 26.8). The most frequent adverse events were nausea, vomit- ing, diarrhea and neutropenia, the majority grade 1-2, according to Common Terminology Criteria for Adverse Events (CTCAE) classification. Conclusions In patients studied, the FOLFOX-4 combination was shown to be an effective and well-tolerated therapeutic option for treating inoperable metastatic colorectal cancer.read more
Citations
More filters
Journal ArticleDOI
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study
TL;DR: Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy and mean serum levels of malondialdehyde and neurotensin were significantly lower after the 6th and the 12th cycles.
Journal ArticleDOI
Interstitial lung disease in a patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for metastatic colorectal cancer
TL;DR: Although infrequent, pulmonary toxicity can occur in association with FOLFOX therapy and Cessation of therapy and prompt initiation of corticosteroids may improve outcomes.
References
More filters
Journal ArticleDOI
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
Sylvie Giacchetti,B. Perpoint,Rachid Zidani,N. Le Bail,R. Faggiuolo,Christian Focan,Philippe Chollet,J.F. Llory,Y. Letourneau,Bruno Coudert,F. Bertheaut-Cvitkovic,D. Larregain-Fournier,A. Le Rol,Stephen D. Walter,Rosalyn M. Adam,J.L. Misset,Francis Lévi +16 more
TL;DR: By chronomodulating 5-FU-LV, the authors were able to add l-OHP without compromising dose-intensities and significantly improved the antitumor efficacy of this regimen.
Journal ArticleDOI
Systemic Therapy for Colorectal Cancer
TL;DR: This review considers recently developed cytotoxic chemotherapies and biologic agents that are effective against colorectal cancer and assesses their use as treatments for metastatic disease and as components of adjuvant therapy.
Journal ArticleDOI
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
TL;DR: In this sample of patients with disseminated colorectal cancer the chemotherapy regimen was an effective form of palliative treatment and in patients with abnormal scores before treatment, quality of life seemed better in the chemotherapy arm.
Journal ArticleDOI
Chronomodulated Versus Fixed-Infusion—Rate Delivery of Ambulatory Chemotherapy With Oxaliplatin, Fluorouracil, and Folinic Acid (Leucovorin) in Patients With Colorectal Cancer Metastases: a Randomized Multi-institutional Trial
Francis Lévi,Rachid Zidani,J.-M. Vannetzel,B. Perpoint,Christian Focan,R. Faggiuolo,Philippe Chollet,Carlo Garufi,M. Itzhaki,L Dogliotti +9 more
TL;DR: This ambulatory treatment modality was both more effective and less toxic if drug delivery was chronomodulated rather than constant over time, as determined in another trial in patients with previously untreated metastatic colorectal cancer.
Journal ArticleDOI
Oxaliplatin-safety profile: neurotoxicity.
TL;DR: The predictability of neurotoxicity associated with oxaliplatin-based therapy should allow patients and doctors to develop strategies to manage this side effect in view of the individual patient's clinical situation.